Wuxi Capital Group leads investment in Zhikang Hongyi, raising hundreds of millions of yuan in Series A+financing

　　On July 31st, Zhikang Hongyi announced the successful completion of hundreds of millions of yuan in A+round financing. This round of financing is led by Wuxi Capital Group and Binhu Industrial Group, with existing shareholders of companies such as WuXi Biologics continuing to make additional investments.

　　As an innovation driven biotechnology enterprise, Zhikang Hongyi attaches great importance to its "science+business" dual wheel drive concept. With disease biology and translational medicine research as its core competitiveness, it is committed to conducting research on new targets and mechanisms in its target fields.

　　Zhikang Hongyi is currently actively promoting the clinical development of multiple innovative drugs with the potential for "global first and best in class" in fields such as cancer and kidney disease. Among them, the tumor core product - the globally exclusive ADC drug BC3195 targeting CDH3- is conducting dose expansion studies in multiple cohorts of Phase Ib clinical trials simultaneously in China and the United States; The core product of kidney disease - potential best in class high selectivity ETA small molecule antagonist SC0062 trial is about to complete Phase II 2-SUCCEED clinical research, and is currently in active communication with regulatory agencies, striving to launch Phase III clinical trials within the year.